News headlines about Agile Therapeutics (NASDAQ:AGRX) have trended positive on Saturday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a news impact score of 0.28 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 47.0261829004423 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
AGRX has been the subject of several research analyst reports. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $5.00 price objective on shares of Agile Therapeutics in a report on Friday, December 22nd. HC Wainwright set a $8.00 price objective on Agile Therapeutics and gave the company a “buy” rating in a report on Friday, December 22nd. William Blair downgraded Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. Finally, Janney Montgomery Scott downgraded Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $9.20.
Agile Therapeutics (NASDAQ AGRX) traded up $0.04 during mid-day trading on Friday, hitting $3.69. The company had a trading volume of 120,917 shares, compared to its average volume of 277,789. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10. The company has a market capitalization of $127.53, a P/E ratio of -4.01 and a beta of 2.15. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60.
COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://ledgergazette.com/2018/02/17/agile-therapeutics-agrx-given-media-impact-score-of-0-28.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.